LIXIL-FOUNDATION
28.10.2016 07:02:53 CEST | Business Wire | Press release
The LIXIL Foundation (located in Koto-ku, Tokyo; Chairman: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, is pleased to announce today that the next-generation sustainable housing “INFINITE FIELD” designed by The Royal Danish Academy of Fine Arts (Denmark) has been completed on a site of Memu Meadows in Taiki-cho Hokkaido, environmental technology research facilities managed by the foundation.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161027007034/en/
INFINITE FIELD is the top prize winner in the 6th LIXIL International Student Architectural Competition sponsored by the LIXIL Foundation, aimed to seek and review next-generation sustainable housing technology and communicate that technology to the global community. The project was designed based on the theme: “Comfort and Lightness.” For the first time in its history, this year’s competition called for proposals for a light shelter that can be easily assembled and moved.
INFINITE FIELD is a structure that features a 360-degree timber platform and the design enveloped by soft, permeable membranes. From this elevated platform, which is aligned with an average snow depth in this region, users are able to enjoy the view of snowfield spreading infinitely during the winter months while the platform transforms into a place to cool off in the summer heat. It is designed to allow people to feel changes of the seasons in Taiki-cho.
The varied textile membranes invite nature in and allow the architecture in itself to move. The fabric is layered to create the space; these textiles are chosen with consideration of various environmental properties to ensure a comfortable thermal environment. Dwellers can operate these layered membranes on their own, adding or removing them to adjust their relationships with the environment while they serve as an expanded threshold.
With the completion of INFINITE FIELD, Memu Meadows is now a home to six structures designed by students. The effects of these “next-generation sustainable houses” will continue to be verified.
|
Accompanying Material |
||||||||
|
-- INFINITE FIELD designed by The Danish Royal Academy of Fine Arts (Denmark) |
||||||||
|
Supervisor: |
Anders Brix, Professor | |||||||
|
Students: |
Kazumasa Takada/Bas Spaanderman | |||||||
| Scarlett Emma Hessian/Jesse Thomas | ||||||||
| Benjamin Hock Yuu Tan/Konstantinos Fetsis | ||||||||
|
Design Supervisor: Kengo Kuma & Associates |
Structural Engineer: Oak Structural Design |
|
|
General Contractor: Takahashi Construction Company |
Building Area: 21.3m2 |
|
|
Construction Cost: Approx. 15 million yen |
||
|
Construction Period: August 2016 - October 2016 |
||
[Features]
-
Seasonal Transformation
INFINITE FIELD was imagined as a permeable experience, one where users are able to dictate their conditions, while engaging with the natural environment surrounding them. During the winter months it is from this elevated vantage point that users are aligned with an infinite sea of snow, and are treated to overlook the landscape from the warmth of the nest. In the summer heat the platform transforms into a place for rest and quiet reflection, looking out to a field of wild grasses, trees and bright blue skies. This 360-degree timber base is a contemplative oasis providing panoramic views of the natural surrounding. -
Spatial Tactility
INFINITE FIELD is an architecture of change and graduation, allowing users to experience and enjoy the shifting environment in comfort, while simultaneously enhancing our human connection with nature. A set of soft, permeable membranes made of varied textiles invites nature in and allows the design to move and breathe with the seasons. As you transition across the platform users can operate the membranes, moving them to add or remove barriers between the environment and themselves. These layers are an expanded threshold, an envelope inviting nature in while allowing a tactile interaction with the architecture. -
Material
Dwelling
The fabric architecture imparts a whole new perspective to familiar scenes. Silk fabric blades hang from the draped inner membrane disrupting heat and air flow. Users are able to visually perceive the gentle winds and air that flow through the dwelling as these fabric blades gently sway and flutter in the breeze. The project’s textiles are chosen with consideration of the various environmental properties, while their layered design provides adaptable thermal zones for user’s personal comfort.
-- Overview of Facility
Name:
Memu Meadows
Location:
158-1 Memu, Taiki-cho, Hiro-gun, Obihiro, Hokkaido
Owner:
LIXIL Foundation 2-1-1 Ojima, Koto-ku, Tokyo, 136-8535
Site
area:
App. 184,000 square meters
Main facilities:
Experimental
house “Même”, “Mock-up of Multiple floor Bamboo House”, “A recipe to
live”, “BARN HOUSE”, “HORIZON HOUSE”, “NEST WE GROW”, “INVERTED HOUSE”,
Multipurpose Facility, Conference Pavilion, Residence 1L and 1R
(accommodation for researchers), two log houses (accommodation for
researchers), fitness center, restaurant, Administration Wing, etc.
Official
website:
http://www.lixiljsfound.com/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027007034/en/
Contact:
LIXIL Foundation
Kenji Iida, +81-3-5626-1008
2-1-1, Oshima,
Koto-ku, Tokyo 136-8535
Fax: +81-3-5626-1033
LIXIL Foundation
website: http://www.lixiljsfound.com/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
